» Articles » PMID: 2526328

Biologic Activity of 5'-deoxy-5-fluorouridine by Rectal Administration

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1989 Apr 1
PMID 2526328
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

5'-Deoxy-5-fluorouridine (dFUR) is used orally to treat human malignancies. This study compared the antitumor activity and toxicity of rectally and orally administered dFUR. A 7-day treatment of dFUR (350 or 700 mg/kg/day) was infused rectally over 30 min or administered by oral gavage (500 mg/kg/day) to rats bearing transplanted dimethylhydrazine-induced colon tumors. The oral treatment was previously shown to produce a 82% cure of the tumor-bearing animals. The tumor weight after 7 day treatment was compared to that before treatment. The size of the tumor in the saline-treated control group (N = 6) increased by 55%. The maximum tumor size reductions by drug treatments were 40% for the 350-mg/kg rectal dose (N = 5), greater than 99% for the 700-mg/kg rectal dose (N = 10), and 100% for the 500-mg/kg oral dose (N = 4). The 350-mg/kg rectal dose did not produce any cures, while the 700-mg/kg rectal dose produced 80% cures and the 500-mg/kg oral dose 100% cures. The cured animals remained tumor-free during the observation period of 163 to 243 days. The tumor-bearing rats were euthanized between 46 and 132 days when they appeared moribund or when the tumor began to ulcerate. The 700-mg/kg rectal and 500-mg/kg oral treatments produced greater weight loss than saline suggesting a drug-induced intestinal toxicity. After rectal drug treatment, the animal weight returned to pretreatment level within 3 days, indicating a rapidly reversible intestinal toxicity. The oral group suffered a greater weight loss than the rectal group and took more than 10 days to recover.2+his suggests that the intestinal

Citing Articles

Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Bramer S, Wientjes M, Au J Pharm Res. 1993; 10(5):763-70.

PMID: 8321843 DOI: 10.1023/a:1018928320449.


Absorption of 5'-deoxy-5-fluorouridine from colon.

Au J, Gunnarsson L Pharm Res. 1989; 6(4):323-7.

PMID: 2526329 DOI: 10.1023/a:1015902625456.

References
1.
Trave F, Canobbio L, Au J, Rustum Y . Role of administration route in the therapeutic efficacy of doxifluridine. J Natl Cancer Inst. 1987; 78(3):527-32. View

2.
de Leede L, De Boer A, Roozen C, Breimer D . Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats. J Pharmacol Exp Ther. 1983; 225(1):181-5. View

3.
Au J, Rustum Y, Slocum H . Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats. Cancer Drug Deliv. 1987; 4(3):137-44. DOI: 10.1089/cdd.1987.4.137. View

4.
Abele R, Alberto P, Seematter R, Germano G, HEINTZ R, BOLLAG W . Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. Cancer Treat Rep. 1982; 66(6):1307-13. View

5.
Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C . A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg. 1985; 72(5):359-63. DOI: 10.1002/bjs.1800720509. View